PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
First patients enrolled on the Veris Cancer Care Platform
NEW YORK, June 13, 2024 /PRNewswire/ — PAVmed Inc. (Nasdaq: PAVM) (“PAVmed” or the “Company”) a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. (“Veris”), today announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.